Prostatitis Treatment Market and Diagnoses Both Increasing

May 31, 2019

Prostatitis

Advertisement

Recently there has been an increase in the prostatitis treatment market, especially in the United States and Canada. The reason behind the surge appears to be growth in extensive research and development in this area of prostate health. More prostatitis treatment options and advances are coming to market, and this is being met by more men being diagnosed and a broader recognition of the problem.

According to the Prostatitis Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2026, prostatitis treatment in North America, which is currently the largest market, has been successful, and success will boost growth in this health segment. In addition, other promising signs include a healthcare infrastructure, an improving reimbursement scenario, and some positive initiatives from the government to implement prostatitis treatment.

Europe is the second largest prostatitis treatment market, and this is due to improved healthcare processes and implementation of enhanced healthcare concerns among the countries. In the Asian Pacific countries, which includes China, India, and Japan, the main factor that will prompt the prostatitis treatment market is the rising number of men who are being diagnosed with the condition.

In South America, forecasters see significant potential for growth, especially in Mexico and Brazil, because of their evolving medical infrastructure and rising levels of disposable income.

Advertisement

Current prostatitis treatment options

Prostatitis can appear as one of four different forms, although chronic pelvic pain syndrome (CPPS) is by far the most common, representing 90 to 95 percent of all cases of this prostate condition. The other three are acute bacterial prostatitis, chronic bacterial prostatitis, and asymptomatic prostatitis.

Many treatment approaches are available for CPPS, and the list keeps growing. The list of medication options is quite extensive and includes nonsteroidal anti-inflammatory drugs, 5-alpha reductase inhibitors, alpha blockers, muscle relaxers, and antidepressants. All are associated with varying numbers and degrees of side effects.

Alternative treatment methods include various supplements (e.g., quercetin, pollen), acupuncture, stress management techniques, prostate massage, biofeedback therapy, cognitive behavioral therapy, trigger point release, pelvic rehabilitation, and pelvic floor exercises, among others. One of the most recent additions is treatment being offered mainly in China, called 3D prostate targeted treatment. It involves minute herbal injections into the prostate and has been gaining attention from men around the world.

For men who have acute or chronic bacterial prostatitis, antibiotics are the mainstay treatment. In addition, there is a growing interest in the use of probiotics, along with the antibiotics, for relieving urinary symptoms associated with these forms of prostatitis. However, they also may have a place in the treatment of CPPS.

In a new review, for example, the authors of a study appearing in European Urology Focus noted that “Changes in the microbiome have been observed in certain urologic disorders such as…chronic prostatitis/chronic pelvic pain syndrome” and that “the role of probiotics, prebiotics, and diet as treatment or preventive agents…requires further investigation.”

Bottom line

The forecast for the prostatitis treatment market is growth! Men who have prostatitis or those who may be diagnosed with this common prostate condition should be aware of the many treatment options and stay abreast of innovations in the field.

References

  • Aragon IM et al. The urinary tract micribiome in health and disease. European Urology Focus 2018 Jan; 4(1): 128-38
  • Digital Journal. 3D prostate targeted treatment reviews now available online for people to get complete information about the revolutionary 3D prostate targeted treatment. 2019 May 3
  • Digital Day News. Prostatitis treatment market to grow at a high rate owing to increase in patient number with prostatitis. 2019 Apr 24

Advertisement